Grenoble, France, 7th January 2013 – CYTOO, a life science systems & tools company providing disruptive solutions
for cell-based assays and High Content Screening (HCS), will attend the Society for Laboratory Automation and
Screening (SLAS) 2013 conference in Orlando, Florida, USA. The company will present their 2D+ Solutions, opening
fresh perspectives for cell based assay development in drug discovery.
2D+ Solutions are based on CYTOO’s standard and custom adhesive micropatterns in 96-well plates which guide cell
architecture and behavior. By defining the 2D topology of cell adhesion, the 2D+ Cell Culture Platform enables fine
control of the spreading and 3D shape of cultured cells in single- or multi-cellular configurations. This approach
results in control of cell contractility, cell polarity, organelle positioning, and cell division axis.
2D+ Custom Solutions are specifically designed to bring expertise, resources and technology to address current
bottlenecks in cell based assay development and screening in drug discovery.
2D+ Custom Solutions include: Exploratory solutions to guide customers through the initial exploration of the 2D+
technology with experienced PhD-level expert support; Assay development to select the best ecosystem for the
requested cells; Screening to run pilot or full sized screens. All Solutions are tailored to the customer’s needs and can
be carried out in the customer’s facilities or outsourced to CYTOO, on our fully equipped HCS screening platform.
The 2D+ technology addresses a major concern with traditional 2D culture, in which cells spread and move in an
uncontrolled manner, introducing a considerable but unnoticed variability in cell function. Kristine Schauer, from the
Institut Curie in Paris, France, used the crossbow adhesive micropatterns to get reproducible shape and distribution
of intracellular compartments and developed a mathematical algorithm to generate and compare probabilistic
density maps of the different endosome compartments.
This innovative approach is a powerful universal method to identify statistically relevant hits and drug effects in
complex cell based assays, and according to Michel Bornens, COO at CYTOO “the method has now the potential to
become a gold-standard in the quantitative analysis of cell-based high-throughput data”. Kristine Schauer’s
Organelle Map figures among the nine 2013 SLAS Innovation Award finalists. A $10,000 cash prize will be attributed
during SLAS 2013, and recognizes extraordinary achievement in innovative laboratory science and technology.
Attendees are invited to visit booth #310 to discuss their application with François Chatelain, President and CEO,
and Lisa Minor, Application Development Leader.
For more information, visit www.cytoo.com
Alexandra Fuchs, PhD, COO
firstname.lastname@example.org, +33 (0)4 38 88 47 07
About CYTOO S.A.
CYTOO is a distinctive life sciences systems & tools company offering disruptive solutions for cell-based assays and
High Content Screening (HCS) that reinforce robustness, sensitivity and powerful quantification. The Company’s 2D+
Cell Culture Platform and Custom Solutions are based on adhesive micropatterns, offering control over the cells'
microenvironment, leading to normalized cell morphology and behavior. The technology allows the optimization or
resurrection of complex or difficult cell-based assays and enables innovative assay development.
For more information about the complete product portfolio, visit www.cytoo.com